Terns Pharma (TERN) Clinical Update

Terns Pharmaceuticals filed an 8-K detailing updated data for its CML drug candidate, TERN-701, ahead of its Dec 8 ASH oral presentation.

• Trial Status: Phase 1 CARDINAL trial data cutoff June 30, 2025. Dose expansion ongoing (320mg or 500mg QD).
• Efficacy Highlights (32 efficacy-evaluable patients):
  • Overall cumulative Major Molecular Response (MMR) by 24 weeks: 75%.
  • MMR in difficult-to-treat subgroups (TKI failure): 69%.
  • MMR in patients pre-treated with asciminib: 60%.
• Safety: Dose escalation